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Background: Uremic pruritus is a common and deleterious condition among hemodialysis (HD) patients. Central
gating of μ/κ opiate circuitry plays an important role in mediating and countering pruritogenic sensation. The
objective of this study was to assess the safety and pharmacokinetics (PK) of the mixed μ-antagonist/κ-agonist
nalbuphine, administered orally as nalbuphine HCl extended release (ER) tablets in HD patients, and explore its
effect on pruritus.
Methods: In this open-label multiple escalating dose study, 15 HD patients with pruritus and 9 matched healthy
subjects were enrolled. Nalbuphine HCl ER dose was escalated from 30 mg QD to 240 mg BID over 15 days. A full
PK profile was obtained under dialysis and non-dialysis conditions as a function of dose. Clearance during dialysis
was determined by sampling dialysate and arterial/venous blood during dialysis. Pruritus severity was assessed twice
daily using a Visual Analog Scale (VAS). Safety monitoring included extensive monitoring of EKG, blood pressure,
and pulse oximetry.
Results: In HD patients, nalbuphine concentration peaked within 4–9 hours and attained steady state within 2–3
days, with no significant accumulation. Mean half-life was 14.2 hours, mean Cmax and AUCtau ranged between 13
and 83 ng/mL and 118 and 761 ng∙h/mL, respectively, with exposure increasing in a nearly dose-proportional fashion.
Exposure in HD patients was about 2-fold higher than in healthy subjects. There was no meaningful difference between
exposure on dialysis and non-dialysis days with 1% or less of the dose removed by dialysis. Nalbuphine suppressed itch
in a dose-dependent manner, reducing mean VAS score from 4.0 to 1.2 at 180 mg and 0.4 at 240 mg.
Conclusions: Nalbuphine HCl ER tablets can be safely administered to HD patients without dose adjustment up to
240 mg BID and may hold promise in treating uremic pruritus.
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Uremic pruritus is an itch disorder associated with end-
stage renal disease (ESRD) that can be severe and debilitat-
ing. In its most severe form, uremic pruritus is associated
with significant deleterious impairments of patient quality
of life, including depression and disruption of sleep [1,2].
A 17% increase in mortality rate (p < 0.001), attributed to
sleep disturbances, is associated with moderate to severe
pruritus [2,3]. Uremic pruritus is independent of gender,* Correspondence: Thomas.sciascia@trevitherapeutics.com
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underlying renal disease [3,4]. Among the factors causing
pruritus in ESRD patients are accumulation of uremic
toxins, systemic inflammation, cutaneous xerosis, and
common comorbidities, e.g. diabetes mellitus and viral
hepatitis (4). Currently, there are no approved treatments
in the United States or Europe. Uremic pruritus is typically
treated with creams, antihistamines, ultraviolet radiation,
and the off-label use of various drugs, including opioids,
with limited success [4-6]. To date, uremic pruritus re-
mains an unresolved problem with renal transplantation
being the only effective treatment [7,8].his is an Open Access article distributed under the terms of the Creative
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has evolved considerably over the past decade as the
underlying pathophysiology of pruritus sensation and
itch are more rigorously investigated. A mechanistic hy-
pothesis related to peripheral neuropathic changes and
central nervous system pathobiology along with evidence
for cutaneous microinflammation has recently emerged
[6,9]. As such, pruritus and pain are believed to share
many neurophysiological processes, yet distinct path-
ways [4]. While central μ-opioid receptor agonism in-
duces itching that can be abolished with μ-antagonists,
κ-opioid receptor agonism inhibits the μ-receptor-
mediated scratching [10,11]. Thus the central gating of
μ/κ opiate circuitry could be important in countering
pruritogenic sensation from a peripheral neurogenic in-
flammatory initiating event in uremic pruritus [12,13].
In addition to a potential neurophysiological mechan-
ism connected to opioid receptor biology, uremic prur-
itus has been correlated to an imbalance between the
endogenous opiate ligands beta-endorphin (μ-agonist)
and dynorphin A (κ-agonist), resulting in an increased
beta-endorphin to dynorphin A serum ratio in uremic pa-
tients compared to healthy volunteers [11]. Clinical study
data support a role for opioid receptors in mediating itch
processing in uremic pruritus: nalfurafine HCl, a pure κ-
opioid receptor agonist, has been shown to reduce itch se-
verity and sleep disturbances in uremic pruritus patients
[14,15], while naltrexone, a μ-antagonist, has shown some
beneficial effect in relieving uremic pruritus-associated
itch, although with more limited success [16].
Nalbuphine is a mixed μ-antagonist/κ-agonist opioid
drug [17], currently marketed as Nalbuphine HCl for In-
jection for use in the relief of moderate to severe pain
[18]. In addition, nalbuphine has been shown to attenu-
ate morphine-induced pruritus in a number of well-
controlled, clinical studies [19-23]. More recently, nal-
buphine was shown to significantly reduce Substance-P
induced itch in a mouse model [24]. In view of its dual
agonist/antagonist mechanism of action, nalbuphine
may be effective at reducing pruritus by rebalancing
opioid μ and κ neuronal activity.
An extended release (ER) nalbuphine solid oral dosage
form was developed to facilitate drug administration and
patient adherence. Understanding nalbuphine disposition
following oral administration in the target HD patient
population is critical as the effects of renal impairment on
opioid clearance are variable [25-27]. This study was de-
signed to assess the safety and pharmacokinetics (PK) of
nalbuphine administered orally as nalbuphine HCl ER tab-
lets in renally-impaired HD patients with pruritus follow-
ing repeated escalating doses over a 6-fold dose range, and
to determine whether nalbuphine is cleared by dialysis. In
addition, the effect of nalbuphine on uremic pruritus
was explored.Methods
This study was sponsored by Trevi Therapeutics and con-
ducted in accordance with the Declaration of Helsinki. All
aspects of the study were conducted in accordance with
national, state, and local laws and regulations. The study
was registered at clinicaltrials.gov (NCT02373215) and the
study protocol, all amendments, and informed consent
form (ICF) were reviewed and approved by the Investiga-
tor, clinic staff, and Institutional Review Board (Western
Institutional Review Board, Olympia, WA). All patients
provided written, signed informed consent prior to enter-
ing the study and before any study-related procedures
were performed.
Study drug and administration
Nalbuphine HCl ER tablets (30 mg) were provided by
Trevi Therapeutics. Unless specified, doses were admin-
istered as multiples of 30-mg tablets to achieve the de-
sired dose and with water (120 ml) 12 hours apart with
food. All subjects received a renal/diabetic diet. For HD
patients on dialysis days, the morning dose was adminis-
tered no earlier than 6 hours and no later than 4 hours
prior to dialysis; the evening dose was administered after
the end of dialysis, 12 hours after the morning dose.
Study subjects
Study subjects were 18–70 years of age. HD patients
with Stage 5 chronic end-stage renal disease (ESRD) re-
quiring dialysis reported at least mild intermittent prur-
itus at Screening (according to the clinical pharmacology
unit Checklist of Common Symptoms of Dialysis
Patients); had been undergoing dialysis 3x/week for at
least 3 months with Kt/V >1.1 with no significant alter-
ation in regimen within 2 weeks prior to Screening; and
had hemoglobin > 9 g/dL at Screening. HD patients
with alanine and/or aspartate aminotransferase concen-
tration >2X the upper limit of normal range (ULN) and
serum total bilirubin >1.8X ULN at Screening were ex-
cluded. Factors that may impact pruritus severity such
as predialysis phosphate, urea and CRP levels were not
examined in this study.
Healthy subjects were matched with HD patients for
body mass index (BMI; within 15%), age (within
10 years), and gender. For all subjects, exclusion criteria
included known hypersensitivity to nalbuphine or opi-
oids; pregnancy or lactation; abnormal laboratory values
considered clinically significant by the Investigator; and
receipt of barbiturates, amphetamines, or opiates within
7 days prior to check-in.
Study design
The study was an open-label, single site, multiple escal-
ating dose study comprised of 2 cohorts. Per protocol,
Cohort 1 consisted of 14 HD patients divided into four
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2, 3, and 4, respectively. Cohort 2 consisted of 8 healthy
subjects. Subjects who discontinued study prior to
reaching the final dose level (180 mg or 240 mg) were
replaced. The targeted number of subjects is within the
range of sample sizes used in similar Phase 1 clinical
studies and is not based on a formal statistical power
calculation.
Subjects received a single 30-mg dose on Day 1. Doses
were subsequently escalated to twice daily (BID) 30 mg,
60 mg, 120 mg, 180 mg over 13 days or to 240 mg BID
over 15 days (Cohort 1, Group 4 only). On the last treat-
ment day, subjects received a single 180-mg or 240-mg
dose in the morning. Subjects remained at each dose
level for 2–3 days (minimum 4 consecutive doses) with
dose escalation predicated on tolerability of the prior
dose. Subjects remained in the clinic from Day −1 until
discharge on Day 14 (~30 hours after last dose) or Day
17 (~54 hours after last dose for Cohort 1, Group 4). Sub-
jects returned 5–7 days after discharge for safety follow-
up evaluations. For subjects in Cohort 1, dialysis was
conducted at approximately the same time on Days −1, 3,
5, 7, 10, 12, 14 (and Day 17 for Group 4) over 3–3.5 hours
using a high-flux dialyzer with polysulfone membrane
(Additional file 1).
Dosing of subjects in Cohort 1 Groups 1–4 was stag-
gered to allow for an interim medical safety review and
PK analysis. Since healthy subjects were matched to HD
patients, dosing of Cohort 2 was not initiated until
Cohort 1 Groups 1–3 were complete and the dosing
regimen confirmed. All subjects in Cohort 2 were dosed
concurrently. A study schematic is provided in Figure 1.
Pharmacokinetic analyses
Pharmacokinetic analyses were conducted following US
Food and Drug Administration (US FDA) Draft Guidance
For Industry On Pharmacokinetics In Patients WithFigure 1 Study schematic.Impaired Renal Function (2010). Analyses included all
subjects who received at least 1 dose of study drug and
had plasma concentration data above the lower limit of
quantitation. Details of sample collection and bioanalytical
methods are provided in Additional file 1. Pharmacoki-
netic parameters were calculated using noncompartmental
analysis with WinNonlin Professional v6.2.1 (Pharsight
Corporation, Cary, NC). Parameters included area under
the plasma concentration-time curve (AUC) from time
zero extrapolated to infinity (AUCinf); AUC from time
zero to last measurable concentration (AUClast); AUC over
the 12 hour dosing interval (AUCtau); accumulation ratio
(ARAUCtau , based on AUCtau Day 4/ AUCtau Day 1); area
under the arterial plasma concentration versus time from
beginning to end of dialysis (AUCd); maximum observed
plasma concentration (Cmax); time of maximum observed
plasma concentration (Tmax); and plasma half-life (T1/2).
Dialysate parameters included amount of drug removed
during dialysis for each collection interval (Arem(t1-t2));
percentage of total amount of drug recovered in the di-
alysate (%Arem) calculated as Arem(0-end)/dose; and dialy-
sis clearance (CLd; Arem[0end]/AUCd).
Statistical analyses
All statistical analyses were performed using SAS v9.1.3
(SAS Institute Inc, Cary, NC). Pharmacokinetic parame-
ters were summarized using descriptive statistics
(n, mean, standard deviation [SD], minimum and max-
imum values, and percentage coefficient of variance
[CV]). Descriptive statistics for Tmax were summarized
using n, median, minimum, and maximum values. Geo-
metric mean and CV values were derived for plasma Cmax,
AUClast, AUCtau, AUCd, %Arem, and T1/2. Attainment of
nalbuphine steady-state was assessed based on visual com-
parison of trough concentrations. The effect of renal im-
pairment on nalbuphine PK was assessed by analysis of
variance (ANOVA) on the natural log transformed PK
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days using a general linear mixed effect model and meas-
uring the amount of drug removed in the dialysate.
Visual analog scale assessment of itch severity
Patients self-reported twice a day their worst daytime
and nighttime itch intensity using a visual analog scale
(VAS) of 0 (none) to 100 mm (maximal possible inten-
sity) itch score. Patients drew a vertical line between “0”
and “100” to denote the worst itching. All VAS values
were converted to a scale of 0–10 by dividing the ob-
served value by 10. The average worst VAS score and
change from baseline were calculated for each HD pa-
tient at each dose level. Baseline VAS score was defined
as the average of the values obtained pre-treatment. Data
were summarized using descriptive statistics.Safety
Safety assessments included the evaluation of adverse
events (AEs), clinical laboratory results (serum chemis-
try, hematology, urinalysis), vital signs (systolic and dia-
stolic blood pressure, pulse rate, respiratory rate, body
temperature) and extensive oxygen saturation (SpO2)
monitoring, 12-lead electrocardiogram (ECG) measure-
ments, and physical examination findings.Results
Patient characteristics
A total of 24 subjects in 2 cohorts were enrolled: 15 HD
patients were enrolled in Cohort 1 (12 males and 3 fe-
males), of whom 14 completed the study and 1 discon-
tinued; 9 healthy subjects were enrolled in Cohort 2 (7
males and 2 females), of whom 8 completed the study
and 1 discontinued. Healthy subjects were matched to
HD patients for gender, BMI and age. Patient character-
istics are presented in Additional file 1: Table S1.Figure 2 Plasma concentration of nalbuphine in hemodialysis patient
and a single 180-mg dose on day 13 administered orally as nalbuphiSafety
Nalbuphine was well tolerated in all subjects. The most
commonly reported treatment emergent AEs (TEAEs)
were gastrointestinal and nervous system disorders con-
sistent with the opioid class of drugs. One HD patient
discontinued on Day 3 due to a serious AE (SAE) that
was considered unlikely to be study drug related. A sec-
ond HD patient discontinued due to a nonserious, pos-
sibly related, Grade 3 report of vertigo after receiving
two 240-mg doses; this subject was not replaced. Among
healthy subjects, 1 subject discontinued due to a nonse-
rious combined report of Grade 1 gastroesophageal re-
flux disease, nausea, and vertigo at the 120-mg dose. No
deaths were observed in either cohort and there were no
apparent treatment-related trends in clinical laboratory
assessments, vital sign and SpO2 measurements, ECG
results, or physical examination findings.
Pharmacokinetics
Mean plasma concentrations for Day 1 and Day 13 as a
function of time for HD patients and healthy subjects
are shown in Figure 2. In HD patients, nalbuphine
plasma profile was characterized by a slow rise in con-
centration, reaching a peak within 4–9 hours. For many
subjects, plasma profiles were characterized by a double
peak pattern, which is suggestive of enterohepatic recir-
culation. Upon repeated dosing, steady state was
attained within 2–3 days, with no significant accumula-
tion in exposure beyond that expected for repeat-dosing
(ARAUCtau = 2.7; Table 1). Mean Cmax ranged between
13 and 83 ng/mL and AUCtau between 118 and
761 ng∙h/mL. Mean plasma half life (T1/2) was 10.5 and
14.2 hours following a single 30-mg and repeat 180-mg
BID dose, respectively. Exposure (Cmax and AUCtau) in-
creased in a nearly dose proportional fashion over the
30-mg to 180-mg BID dose range: 2-, 4-, and 6-fold in-
creases in dose resulted in approximately 2-, 5-, and 6-
fold increases in mean Cmax, and AUCtau (Table 2). Note,s and healthy subjects following a single 30-mg dose on day 1
ne HCl ER tablets.
Table 1 Mean pharmacokinetic parameters on day 1 and day 13 following multiple nalbuphine oral doses
Parameter Statistics Hemodialysis patients Healthy subjects
30 mg QD 180 mg BID 30 mg QD 180 mg BID
Day 1 Day 13 Day 1 Day 13
AUCinf (ng•h/mL) N 4 4 7 8
Mean 142.5 2635.38 49.53 588.40
SD 33.28 2038.01 30.04 214.08
CV% 23.4 77.3 60.7 36.4
AUClast (ng•h/mL) N 15 9 9 8
Mean 73.43 1457.74 40.55 529.85
SD 41.81 1016.26 22.96 179.93
CV% 56.9 69.7 56.6 34.0
AUCtau (ng•h/mL) N 15 9 9 8
Mean 43.2 760.87 31.53 351.15
SD 24.97 538.28 16.93 118.21
CV 57.8 70.7 53.7 33.7
ARAUCtau ratio Ratio of Mean 2.7 NA 1.6 NA
Cmax (ng/mL) N 15 9 9 8
Mean 6.28 82.78 5.2 44.21
SD 3.36 55.81 2.78 14.54
CV 53.5 67.4 53.5 32.9
Tmax (h) N 15 9 9 8
Min 1.0 2.0 2.0 2.0
Median 5.0 5.0 3.0 4.0
Max 18 7.1 5.0 6.0
T1/2 (h) N 4 4 7 8
Mean 10.49 14.23 6.81 8.58
SD 2.22 3.24 2.79 2.05
CV 21.1 22.7 41.0 23.9
Subjects were titrated every 3–4 days from 30 mg QD on Day 1 to 30 mg BID then 60 mg BID, 120 mg BID and finally 180 mg BID over a 14-day period. Data
shown for Day 1 and Day 13 only.
Abbreviations: ARAUCtau accumulation ratio (mean AUCtau Day 4/Mean AUCtau Day 1), AUCinf area under plasma concentration-time curve from time zero extrapolated
to infinite time, AUClast area under the plasma concentration-time curve from time zero to the last measureable concentration, AUCtau area under plasma concentration-time
curve over dosing interval (0-12 hr), BID twice daily, Cmax maximum observed plasma concentration, CV coefficient of variation, ER extended release, h hour, Max maximum,
Minminimum, n number of subjects, NA not applicable, QD once daily, Tmax time of maximum observed plasma concentration, T1/2 plasma half life.
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ness but were not included in the analysis due to the
small sample size.
In healthy subjects, mean exposure ranged from 5.2
to 44.2 ng/mL for Cmax and from 31.5 to 351.2 ng∙hr/
mL for AUCtau over the 30-mg to 180-mg dose range,
with median Tmax between 2 and 5 hours. As with HD
patients, steady state appeared to be attained within 2–
3 days of dosing, with a modest accumulation in expos-
ure (ARAUCtau = 1.6). Mean T1/2 was 6.8 and 8.6 hours
following a single 30-mg and repeat 180-mg BID dose,
respectively (Table 1, Additional file 1: Table S2). Expos-
ure in HD patients was significantly higher by 65%(Cmax) and 83% (AUCtau) compared to healthy subjects,
while T1/2 was 1.6-fold longer than in healthy subjects
(Additional file 1: Table S3). Overall intersubject vari-
ability was high, particularly in HD patients (CV range
54%-71% for Cmax and AUCtau) compared to healthy
subjects (CV range 33%-56%). An overlay of nalbuphine
plasma concentration profiles as a function of time,
dose, and study day for Cohorts 1 and 2 is shown in
Figure 3.
Effect of dialysis on nalbuphine pharmacokinetics
Mean PK parameters for HD patients on dialysis days
and non-dialysis days as a function of dose are compared
Table 2 Mean pharmacokinetic parameters following multiple escalating oral nalbuphine doses in hemodialysis patients
Parameter Statistics Non-dialysis days Dialysis days
30 mg BID 60 mg BID 120 mg BID 180 mg BID 240 mg BID 30 mg BID 60 mg BID 120 mg BID 180 mg BID 240 mg BID
Day 4 Day 6 Day 9 Day 13 Day 15 Day 3 Day 7 Day 10 Day 12 Day 14
AUCtau (ng•h/mL) n 14 10 10 9 3 11 10 10 13 3
Mean 117.97 221.68 621.79 760.87 769.99 118.56 255.54 582.15 646.06 539.72
SD 76.41 145.04 415.94 538.28 509.88 74.93 157.81 374.09 433.26 476.19
CV 64.8 65.4 66.9 70.7 66.2 63.2 61.8 64.3 67.1 88.2
Cmax (ng/mL) n 14 10 10 9 3 11 10 10 13 4
Mean 13.44 24.78 70.33 82.78 80.47 12.84 27.04 62.51 69.12 63.45
SD 8.31 17.38 48.81 55.81 51.76 7.71 15.74 40.11 47.20 40.10
CV 61.8 70.1 69.4 67.4 64.3 60.1 58.2 64.2 68.3 63.2
Tmax (h) n 14 10 10 9 3 11 10 10 13 4
Min 0 0 3.0 2.0 3.1 2.0 0 0 0 0
Median 4.0 5.0 6.0 5.0 9.0 4.0 4.0 3.5 3.0 2.0
Max 9.0 9.0 9.0 7.1 12.0 11.9 11.9 4.0 11.9 4.0
AUCd (ng•h/mL) n 11 10 10 9
Mean NA NA NA NA NA 40.57 86.87 194.95 280.33 NA
SD 28.14 55.63 136.98 217.42
CV% 69.4 64.0 70.3 77.6
%Arem n 11 10 10 9
Mean NA NA NA NA NA 0.95 1.07 1.24 1.11 NA
SD 0.69 0.74 0.91 0.85
CV% 73.0 69.2 73.1 76.0
CLd
a (L/h) n 11 10 10 9
Mean NA NA NA NA NA 6.98 7.33 7.60 7.32 NA
SD 1.40 1.16 1.30 1.04
CV% 20.1 15.8 17.1 14.2
a Values correspond to 116, 122, 127, and 122 mL/min, respectively.
Abbreviations: %Arem percentage of total amount of drug removed by hemodialysis, AUCd area under arterial plasma concentration-time curve from beginning to end of dialysis, AUCtau area under plasma
concentration-time curve over 12 h, BID twice daily, CLd dialysis clearance, Cmax maximum observed plasma concentration, CV coefficient of variation, ER extended release, h hour, n number of subjects, NA not













Figure 3 Plasma concentration of nalbuphine, administered orally as nalbuphine HCl ER tablets, as a function of day and dose.
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eters are provided in Table 3. Nalbuphine exposure in
HD patients on dialysis days and non-dialysis days was
comparable. The geometric mean ratio for dialysis/non-
dialysis days (90% confidence interval [CI]) was 98.90
(89.73-109.01) for Cmax for all doses; and 91.85 (81.02-
104.12), 94.51 (83.46-107.03) and 94.64 (82.95-107.99)
for AUCtau at the 30, 120 and 180-mg dose levels, re-
spectively. Despite the small number of subjects, the
90% CI for Cmax and AUC0-last were fully contained
within the 80% to 125% confidence limits except at the
60-mg dose, where the upper 90% CI for AUCtau was
outside the upper limit. Regardless, the observed differ-
ence of 18% is small and was not considered clinically
relevant in view of the rather high intersubject
variability.
Analysis of nalbuphine concentration in dialysate indi-
cated that 0.95%-1.24% of the dose was removed during
a standard high-flux 3–4 hour hemodialysis session over
the dosing range (%Arem; Table 2). Clearance during
dialysis (CLd), calculated based on arterial blood sam-
pling from the dialyzer port during dialysis, was 7–
7.6 L/kg (or 116–127 mL/min) and approximated the
creatinine clearance in subjects with normal kidney
function (>90 mL/min).Table 3 Statistical analysis of the effects of hemodialysis on t
Parameter Dose (mg) Na Geometric means
On dialysis (test, T)




Cmax (ng/mL) All doses 15/14 31.04
aNumber of patients on dialysis/non-dialysis days.
Abbreviations: AUCtau area under the plasma concentration-time curve over the dosing
h hour, GMR geometric mean ratio.VAS assessment of itch severity
The impact of nalbuphine HCl ER tablets on uremic prur-
itus was explored in HD patients who self-reported itch
intensity using a VAS score. Nalbuphine suppressed itch
in a dose-dependent manner in 12/14 patients, reducing
itch from a mean VAS score of 4.0 (range, 1.3-6.6) to 1.2
and 0.4 at 180 mg and 240 mg, respectively (Table 4,
Figure 4A). Itch intensity in HD patients is reported to
fluctuate and appears to be cyclical in some patients [1].
However, patients with a baseline VAS above 4 (40 mm)
are reported to have a more persistent itch (daily or nearly
daily) and changes in VAS of at least 20% in either direc-
tion are considered indicative of a change in patient-rated
pruritus severity [1]. Of the 14 patients assessed in this
study, 8 had VAS score ≥4.0 (mean, 5.1; range, 4.2-6.6).
Subgroup analysis of these patients showed a more pro-
nounced change compared to all patients treated, with a
mean change from baseline of –1.2, −2.2, –3.4, −3.6 and
−4.9 at the 30-, 60-, 120-, 180- and 240-mg BID doses, re-
spectively, with the largest incremental changes occurring
between 60 mg and 120 mg BID (Table 4, Figure 4B).
Discussion
Pharmacokinetics of nalbuphine following oral adminis-
tration of nalbuphine HCl ER tablets up to 15 days werehe pharmacokinetics of nalbuphine
Statistics
Non-dialysis (reference, R) GMR (T/R) 90% Confidence limit
94.14 91.85 81.02, 104.12
159.84 117.99 103.56, 134.43
442.56 94.51 83.46, 107.03
599.15 94.64 82.95, 107.99
31.39 98.90 89.73, 109.01
interval, CI confidence interval, Cmax maximum observed plasma concentration,
Table 4 Mean VAS score as a function of nalbuphine oral dose in hemodialysis patients
Dose Statistics VAS score Change from baseline
All patients Patients with VAS ≥ 4.0 All patients Patients with VAS ≥ 4.0
Baseline N 14 8 – –
Mean (SD) 4.0 (1.5) 5.1 (0.8)
Median 4.4 4.9
Min, Max 1.3, 6.6 4.2, 6.6
30 mg BID N 14 8 14 8
Mean (SD) 3.1 (1.9) 3.9 (1.9) −0.9 (1.3) −1.2 (1.5)
Median 2.8 3.2 −0.5 −1.7
Min, Max 0.4, 6.7 1.4, 6.7 −3.2, 0.8 −3.2, 0.8
60 mg BID N 14 8 14 8
Mean (SD) 2.3 (2.0) 2.9 (2.2) −1.7 (1.8) −2.2 (1.8)
Median 1.9 2.8 −1.5 −1.8
Min, Max 0.1, 6.2 0.1, 6.2 −4.3, 1.2 −4.3, 0.8
120 mg BID N 14 8 14 8
Mean (SD) 1.6 (1.8) 1.7 (2.1) −2.4 (1.9) −3.4 (1.9)
Median 0.8 0.9 −2.6 −4.0
Min, Max 0.0. 6.1 0.0, 6.1 −5.5, 0.9 −5.5, 0.7
180 mg BID N 13 7 13 7
Mean (SD) 1.2 (1.6) 1.6 (2.0) −2.8 (1.7) −3.6 (1.8)
Median 0.8 0.8 −2.6 −3.9
Min, Max 0.0, 5.8 0.1, 5.8 −5.1, 0.4 −5.1, 0.4
240 mg BID N 4 2 4 2
Mean (SD) 0.4 (0.5) 0.7 (0.6) −3.1 (2.1) −4.9 (0.8)
Median 0.3 0.7 −2.8 −4.9
Min, Max 0.0, 1.2 0.3, 1.2 −5.5, −1.3 −5.5, −4.3
Abbreviations: BID twice daily, ER extended release, SD standard deviation, VAS visual analog scale.
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matched healthy control subjects. A dose-escalation
study design was selected to mimic nalbuphine use in
uremic pruritus patients in subsequent clinical effi-
cacy studies where patients would start at a low dose
to minimize common opioid AEs such as nausea and
vomiting and allow development of some tolerance
to these particular AEs. Ultimately, nalbuphine would
be titrated to effect, as is standard in opioid treat-
ment, and a washout period between doses would
counter the intent of titration, hence the continuous
escalation from 30 mg to 240 mg in this study. Nal-
buphine is a low molecular weight, water soluble
molecule, with low protein binding (~50%) and a
large volume of distribution (315.5 L) [28,29]. Nalbu-
phine is a high extraction (perfusion-limited) drug
[29], predominantly hepatically cleared in the feces
[30,31]. In HD patients, changes in hepatic blood
flow as well as diffusion of the drug through thedialysis membrane have the potential to affect nalbu-
phine exposure, although the large volume of distri-
bution is expected to offset the dialysis effect. In this
study we show that nalbuphine exposure in HD pa-
tients on non-dialysis and dialysis days was compar-
able over a 6-fold dose range with only 1% of the
dose being removed by dialysis. There was no signifi-
cant drug accumulation, beyond that expected for re-
peat dosing. Collectively, these findings indicate that
no dose adjustment around dialysis treatment is
needed.
Following repeat dosing, nalbuphine exposure in-
creased in a nearly dose-proportional fashion, reaching
steady state within 2-3 days at all dose levels suggest-
ing that additional accumulation due to more pro-
longed exposure is unlikely. Exposure was significantly
higher in HD patients than healthy subjects (83% and
65% increase in AUCtau and Cmax), most likely due to
the longer half-life in HD patients.
Figure 4 Comparison of mean VAS score of itch severity (A)
and change from baseline (B) as a function of nalbuphine HCl
ER dose.
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thus both liver function and genetic differences in drug
metabolizing enzymes and transporters among race
groups could potentially result in variability in
pharmacokinetics. For the marketed Nalbuphine HCl
for Injection, dose reduction is recommended in pa-
tients with hepatic dysfunction [18] since higher expo-
sures are expected. In this study, only subjects with
normal to mild impaired liver function were included
as the effect of significant co-existing liver disease on
nalbuphine safety and exposure in HD patients is not
yet understood. It is also worth noting that there were
more blacks or African Americans enrolled in the HD
group (73%) compared to the healthy subjects (44%).
Whether race played a role in the pharmacokinetic dif-
ferentiation between HD patients and healthy subjects
cannot be gauged from this study due to the small
number of subjects. However, it does underscore the
need for evaluation of the role of polymorphisms inmetabolic pathways on nalbuphine exposure in future
clinical studies.
Assessments of AEs, clinical laboratory results, vital
signs, oxygen saturation, and physical examination find-
ings demonstrated that nalbuphine HCl ER oral tablets
were safe and well-tolerated up to the 240-mg BID dose
tested in HD patients. Moreover, while this study was
not specifically designed to assess effects on uremic
pruritus, discernible reductions in VAS measures of
itch severity did appear to be a function of increasing
nalbuphine dose in HD patients despite the limited
sample size.
Conclusions
In summary, nalbuphine administered as oral nalbu-
phine HCl ER tablets was safe and well-tolerated in
HD patients. Nalbuphine is not extracted by dialysis.
Exploratory investigations suggest that nalbuphine
HCl ER tablets may be effective in reducing pruritus in
HD patients, with particular benefit at doses of 60 mg
BID or higher. Well-controlled clinical efficacy studies
will be conducted to establish the longitudinal effect of
treatment with nalbuphine HCl ER tablets on uremic
pruritus and assess its long term safety.Additional files
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